English Spanish Chinese Russian French Japanese Portuguese Hindi Telugu Tamil

Archive in der Krebsforschung

  • ISSN: 2254-6081
  • H-Index der Zeitschrift: 13
  • Zitierbewertung der Zeitschrift: 3.58
  • Journal-Impact-Faktor: 3.12
Indiziert in
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • CiteFactor
  • OCLC – WorldCat
  • Publons
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Google Scholar
  • Geheime Suchmaschinenlabore
Mehr sehen
Teile diese Seite

Abstrakt

Inhibition of the Cyclin-Dependent Kinases (CDK) 4/6 as Therapy for Estrogen Receptor Positive Breast Cancer

Aurelio B Castrellon, Steven M Nguyen and Luis E Raez

Endocrine therapy (ET) is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer (HR+MBC). However, resistance to ET frequently occurs during the course of treatment. Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET. Cyclin-dependent kinases (CDKs) are a subgroup of serine/ threonine kinases that play a key role in regulating cell cycle progression. In this review, we discuss the currently approved and under investigation CDK 4/6 inhibitors, in addition to their preclinical data and clinical trials that demonstrated their benefit in the treatment of HR+ breast cancer.